Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Current Leases (2020 - 2026)

PROCEPT BioRobotics has reported Current Leases over the past 7 years, most recently at $2.4 million for Q1 2026.

  • Quarterly Current Leases rose 18.91% to $2.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Mar 2026, up 18.91% year-over-year, with the annual reading at $2.2 million for FY2025, 15.92% up from the prior year.
  • Current Leases was $2.4 million for Q1 2026 at PROCEPT BioRobotics, up from $2.2 million in the prior quarter.
  • Over five years, Current Leases peaked at $3.0 million in Q1 2023 and troughed at $1.7 million in Q4 2023.
  • The 5-year median for Current Leases is $2.1 million (2022), against an average of $2.1 million.
  • Year-over-year, Current Leases skyrocketed 37.46% in 2023 and then plummeted 43.26% in 2024.
  • A 5-year view of Current Leases shows it stood at $2.1 million in 2022, then fell by 20.95% to $1.7 million in 2023, then rose by 13.49% to $1.9 million in 2024, then increased by 15.92% to $2.2 million in 2025, then rose by 6.5% to $2.4 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Current Leases are $2.4 million (Q1 2026), $2.2 million (Q4 2025), and $2.1 million (Q3 2025).